Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TY-XXXX
- Development stage
- Preclinical
- Lead developer
- Zhejiang Tongyuan Kang Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TY-XXXX is an undisclosed small molecule cyclin-dependent kinase (CDK) inhibitor currently in preclinical development by Zhejiang Tongyuan Kang Medicine (also known as TYK Medicines). The drug is being investigated for the treatment of solid tumors. While the sponsor has more advanced CDK-targeting assets in its pipeline, such as the CDK4/6 inhibitor TY-302, TY-XXXX represents an earlier-stage program where the specific CDK isoform target (e.g., CDK2, CDK7, or CDK9) has not been publicly disclosed. As a CDK inhibitor, it is designed to disrupt the cell cycle progression of malignant cells, thereby inhibiting tumor growth.
02
Targets
CDK7
Beyond the preview
Go deeper on TY-XXXX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TY-XXXX.